Back to search

Spain· ES:114958001

HARVONI 90 MG/400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

A sofosbuvir and ledipasvir product containing ledipasvir + sofosbuvir, registered in Spain by Gilead Sciences Ireland Unlimited Company. The same ATC class is registered in 13 of our 19 countries.

ATC J05AP51

Checked against AEMPS CIMA (Spain) on

Informational only — not a medical device.

SOURCE REGISTER · ESAEMPS CIMA (Spain)normalisedHARVONI 90 MG/400 MG COMPRIMIDOS RECU…ATCJ05AP51REGISTER NO.ES:114958001PACKS LISTED0CHECKEDSeptember 12, 2026

Where it is registered

Sofosbuvir and ledipasvir is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AP51 (sofosbuvir and ledipasvir), each read from that country’s own register.

  • This record: Spain, from AEMPS CIMA (Spain)
  • 8 of them publish a price we can compare per daily dose

Sofosbuvir and ledipasvir · ATC J05AP51

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

AEMPS CIMA (Spain)
Active substance
ledipasvir + sofosbuvir
Manufacturer
Gilead Sciences Ireland Unlimited Company
Country
Spain (ES)
ATC code
J05AP51
ATC class
Sofosbuvir and ledipasvir
Reimbursed
Not published by this register
Source register
AEMPS CIMA (Spain)
Last checked
September 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Sofosbuvir and ledipasvir in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sofosbuvir and ledipasvir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Harvoni
  • Liechtenstein · Harvoni
  • Norway · Harvoni

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d90ea0a1-0904-4613-8050-b945956c9e80
GET /v1/drugs/d90ea0a1-0904-4613-8050-b945956c9e80?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cpresc": "Diagnóstico Hospitalario",
  "estado": "{\"aut\":1418598000000}",
  "nregistro": "114958001",
  "substance": "ledipasvir + sofosbuvir"
}

See everything about sofosbuvir and ledipasvir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.